Correlates of protection for booster doses of the SARS-CoV-2 vaccine BNT162b2.

Autor: Hertz T; Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel. thertz@post.bgu.ac.il.; National Institute of Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer-Sheva, Israel. thertz@post.bgu.ac.il.; Vaccine and Infectious Disease Division, Fred Hutch Cancer Research Center, Seattle, USA. thertz@post.bgu.ac.il., Levy S; Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.; National Institute of Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer-Sheva, Israel., Ostrovsky D; Clinical Research Center, Soroka University Medical Center, and the faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel., Oppenheimer H; Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.; National Institute of Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer-Sheva, Israel., Zismanov S; Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.; National Institute of Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer-Sheva, Israel., Kuzmina A; Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel., Friedman LM; Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.; National Institute of Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer-Sheva, Israel., Trifkovic S; Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, USA., Brice D; Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA., Chun-Yang L; Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA., Cohen-Lavi L; Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.; National Institute of Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer-Sheva, Israel., Shemer-Avni Y; Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.; Laboratory of Virology, Soroka University Medical Center, Beer-Sheva, Israel., Cohen-Lahav M; Laboratory of Management, Soroka University Medical Center, Beer-Sheva, Israel., Amichay D; Central Laboratory, Clalit Health Services & Dept. of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheba, Israel., Keren-Naus A; Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.; Laboratory of Virology, Soroka University Medical Center, Beer-Sheva, Israel., Voloshin O; Laboratory of Virology, Soroka University Medical Center, Beer-Sheva, Israel., Weber G; Infectious Diseases Unit, Lady Davis Carmel Medical Center, Haifa, Israel.; Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel., Najjar-Debbiny R; Infectious Diseases Unit, Lady Davis Carmel Medical Center, Haifa, Israel.; Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel., Chazan B; Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.; Infectious Diseases Unit, Emek Medical Center, Afula, Israel., McGargill MA; Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA., Webby R; Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, USA., Chowers M; School of Medicine, Tel Aviv University, Tel Aviv, Israel.; Meir Medical Center, Kfar Saba, Israel., Novack L; Clinical Research Center, Soroka University Medical Center, and the faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel., Novack V; Clinical Research Center, Soroka University Medical Center, and the faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel., Taube R; Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel. rantaube@bgu.ac.il., Nesher L; Infectious Disease Institute, Soroka University Medical Center, and Faculty of Health Sciences, Ben-Gurion University, Beer Sheba, Israel. nesherke@bgu.ac.il., Weinstein O; Dept. of Health systems management, faculty of health sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.; Hospital division, Clalit Health Services, Tel Aviv, Israel.
Jazyk: angličtina
Zdroj: Nature communications [Nat Commun] 2023 Jul 29; Vol. 14 (1), pp. 4575. Date of Electronic Publication: 2023 Jul 29.
DOI: 10.1038/s41467-023-39816-4
Abstrakt: Vaccination, especially with multiple doses, provides substantial population-level protection against COVID-19, but emerging variants of concern (VOC) and waning immunity represent significant risks at the individual level. Here we identify correlates of protection (COP) in a multicenter prospective study following 607 healthy individuals who received three doses of the Pfizer-BNT162b2 vaccine approximately six months prior to enrollment. We compared 242 individuals who received a fourth dose to 365 who did not. Within 90 days of enrollment, 239 individuals contracted COVID-19, 45% of the 3-dose group and 30% of the four-dose group. The fourth dose elicited a significant rise in antibody binding and neutralizing titers against multiple VOCs reducing the risk of symptomatic infection by 37% [95%CI, 15%-54%]. However, a group of individuals, characterized by low baseline titers of binding antibodies, remained susceptible to infection despite significantly increased neutralizing antibody titers upon boosting. A combination of reduced IgG levels to RBD mutants and reduced VOC-recognizing IgA antibodies represented the strongest COP in both the 3-dose group (HR = 6.34, p = 0.008) and four-dose group (HR = 8.14, p = 0.018). We validated our findings in an independent second cohort. In summary combination IgA and IgG baseline binding antibody levels may identify individuals most at risk from future infections.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz: